3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Kidney Neoplasms
1
Fatigue
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
6
aldesleukin
6
Cyclophosphamide
6
fludarabine phosphate
5
fludarabine
5
Nivolumab
4
durvalumab
3
Sorafenib
3
Radiotherapy
3
Filgrastim
3
Everolimus
3
Axitinib
3
Temozolomide
2
Peripheral Blood Stem Cell Transplantation
2
Isotretinoin
2
Ipilimumab
2
Interleukin-2
2
Interferon-alpha
2
Fluorouracil
2
Dexamethasone
2
Cyclosporine
2
Bevacizumab
2
vorolanib
1
tremelimumab
1
tocilizumab
1
talazoparib
1
spartalizumab
1
sargramostim
1
poly ICLC
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Kidney Neoplasms
×
isoquercitrin
×
Clear all
NCT02446795
2017-01-18
QUASAR
Consorzio Oncotech
Phase 1/2
Unknown
104 enrolled